Subcutaneous RYBREVANT® (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Medscape

FDA OKs First-Line Lazertinib With Amivantamab for NSCLC

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for upfront treatment of adults with locally advanced or metastatic ...
Medscape

FDA Expands Indication for Amivantamab in Lung Cancer

The US Food and Drug Administration (FDA) has granted a second-line indication to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in non–small-cell lung cancer (NSCLC). Amivantamab with ...
Morning Overview on MSN

How gene mutations disrupt cell growth and trigger cancer?

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...